134 related articles for article (PubMed ID: 12430307)
1. [Beta 3 adrenergic receptor agonist].
Sakura H
Nihon Rinsho; 2002 Oct; 60 Suppl 10():712-8. PubMed ID: 12430307
[No Abstract] [Full Text] [Related]
2. [beta 3-adrenergic receptor agonists as anti-obese and anti-diabetic drugs].
Sakura H; Togashi M; Iwamoto Y
Nihon Rinsho; 2002 Jan; 60(1):123-9. PubMed ID: 11808322
[TBL] [Abstract][Full Text] [Related]
3. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans.
de Souza CJ; Burkey BF
Curr Pharm Des; 2001 Sep; 7(14):1433-49. PubMed ID: 11472270
[TBL] [Abstract][Full Text] [Related]
4. GPR40 is partially required for insulin secretion following activation of beta3-adrenergic receptors.
Pang Z; Wu N; Zhang X; Avallone R; Croci T; Dressler H; Palejwala V; Ferrara P; Tocci MJ; Polites HG
Mol Cell Endocrinol; 2010 Aug; 325(1-2):18-25. PubMed ID: 20416356
[TBL] [Abstract][Full Text] [Related]
5. The effects of beta(3)-adrenoceptor agonist CL-316,243 on adiponectin, adiponectin receptors and tumor necrosis factor-alpha expressions in adipose tissues of obese diabetic KKAy mice.
Fu L; Isobe K; Zeng Q; Suzukawa K; Takekoshi K; Kawakami Y
Eur J Pharmacol; 2008 Apr; 584(1):202-6. PubMed ID: 18304529
[TBL] [Abstract][Full Text] [Related]
6. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
Weyer C; Gautier JF; Danforth E
Diabetes Metab; 1999 Mar; 25(1):11-21. PubMed ID: 10335419
[TBL] [Abstract][Full Text] [Related]
7. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
Arch JR
Eur J Pharmacol; 2002 Apr; 440(2-3):99-107. PubMed ID: 12007528
[TBL] [Abstract][Full Text] [Related]
8. Anti-obesity and anti-diabetic activities of a new beta3 adrenergic receptor agonist, (S)-(Z)-[4-[[1-[2-[(2-hydroxy-3-phenoxypropyl)]amino]ethyl]-1-propenyl] phenoxy] acetic acid ethanedioic acid (SWR-0342SA), in KK-Ay mice.
Kiso T; Namikawa T; Tokunaga T; Sawada K; Kakita T; Shogaki T; Ohtsubo Y
Biol Pharm Bull; 1999 Oct; 22(10):1073-8. PubMed ID: 10549858
[TBL] [Abstract][Full Text] [Related]
9. Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes.
Hu B; Jennings LL
Prog Med Chem; 2003; 41():167-94. PubMed ID: 12774694
[No Abstract] [Full Text] [Related]
10. The beta3-adrenergic agonist CL316,243 inhibits insulin signaling but not glucose uptake in primary human adipocytes.
Jost MM; Jost P; Klein J; Klein HH
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):418-22. PubMed ID: 16151974
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of N-phenyl-(2-aminothiazol-4-yl)acetamides with phenoxypropanolamine moiety as selective β3-adrenergic receptor agonists.
Maruyama T; Onda K; Suzuki T; Hayakawa M; Takahashi T; Matsui T; Takasu T; Nagase I; Ohta M
Chem Pharm Bull (Tokyo); 2012; 60(5):647-58. PubMed ID: 22689403
[TBL] [Abstract][Full Text] [Related]
12. beta3-Adrenergic receptor.
Rehman HU
Heart Dis; 2001; 3(6):349-50. PubMed ID: 11975817
[No Abstract] [Full Text] [Related]
13. Pancreatic beta-cells expressing the Arg64 variant of the beta(3)-adrenergic receptor exhibit abnormal insulin secretory activity.
Perfetti R; Hui H; Chamie K; Binder S; Seibert M; McLenithan J; Silver K; Walston JD
J Mol Endocrinol; 2001 Oct; 27(2):133-44. PubMed ID: 11564599
[TBL] [Abstract][Full Text] [Related]
14. The beta 3-adrenoceptor: physiological role and potential therapeutic applications.
Balligand JL
Acta Clin Belg; 2000; 55(4):209-14. PubMed ID: 11036679
[No Abstract] [Full Text] [Related]
15. Antiobesity and antidiabetic beta-agonists: lessons learned and questions to be answered.
Yen TT
Obes Res; 1994 Sep; 2(5):472-80. PubMed ID: 16353599
[TBL] [Abstract][Full Text] [Related]
16. [Beta 3-adrenergic receptor].
Furutani Y; Karasawa T
Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):935-40. PubMed ID: 10771654
[No Abstract] [Full Text] [Related]
17. Up-regulation of a thermogenesis-related gene (UCP1) and down-regulation of PPARgamma and aP2 genes in adipose tissue: possible features of the antiobesity effects of a beta3-adrenergic agonist.
Margareto J; Larrarte E; Marti A; Martinez JA
Biochem Pharmacol; 2001 Jun; 61(12):1471-8. PubMed ID: 11377376
[TBL] [Abstract][Full Text] [Related]
18. The beta3-adrenoceptor as a therapeutic target: current perspectives.
Ursino MG; Vasina V; Raschi E; Crema F; De Ponti F
Pharmacol Res; 2009 Apr; 59(4):221-34. PubMed ID: 19429463
[TBL] [Abstract][Full Text] [Related]
19. Potent oxindole based human beta3 adrenergic receptor agonists.
Stevens FC; Bloomquist WE; Borel AG; Cohen ML; Droste CA; Heiman ML; Kriauciunas A; Sall DJ; Tinsley FC; Jesudason CD
Bioorg Med Chem Lett; 2007 Nov; 17(22):6270-3. PubMed ID: 17911024
[TBL] [Abstract][Full Text] [Related]
20. Atypical beta-adrenoceptors, different from beta 3-adrenoceptors and probably from the low-affinity state of beta 1-adrenoceptors, relax the rat isolated mesenteric artery.
Kozłowska H; Szymska U; Schlicker E; Malinowska B
Br J Pharmacol; 2003 Sep; 140(1):3-12. PubMed ID: 12967929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
